Fyfe, D <br/><br/>
A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Jan 2002 
 - 1-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>0344-5704 
<br/><br/><label>Standard No.: </label>10.1007/s00280-001-0389-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Amsacrine--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Area Under Curve<br/>Biological Availability<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Injections, Intravenous<br/>Male<br/>Middle Aged<br/>Treatment Outcome